Clinical impact of use of different PSA assays in prostate cancer screening

被引：0
|
作者：
Maciej, Kwiatkowski
Daniel, Seiler
Brigitte, Arndt
Joel, Gregorin
Andreas, Huber [1 ]
Franz, Recker
机构：
[1] Kantonsspital, Ctr Lab Med, Aarau, Switzerland
来源：
TUMOR BIOLOGY | 2007年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：118 / 118
页数：1
相关论文
共 50 条
  • [21] PSA testing for prostate cancer screening
    Castle, Philip E.
    LANCET ONCOLOGY, 2015, 16 (01): : E2 - E3
  • [22] Impact of numeracy on understanding of prostate cancer risk reduction in PSA screening
    Koo, Kevin
    Brackett, Charles D.
    Eisenberg, Ellen H.
    Kieffer, Kelly A.
    Hyams, Elias S.
    PLOS ONE, 2017, 12 (12):
  • [23] IMPACT OF NUMERACY ON UNDERSTANDING OF PROSTATE CANCER RISK REDUCTION IN PSA SCREENING
    Koo, Kevin
    Brackett, Charles D.
    Eisenberg, Ellen
    Kieffer, Kelly A.
    Hyams, Elias S.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2016, 31 : S262 - S263
  • [24] PSA based screening has significant impact on prostate cancer volume
    Steiner, H
    Berger, A
    Spranger, R
    Hager, M
    Moser, P
    Horninger, W
    Bartsch, G
    JOURNAL OF UROLOGY, 2003, 169 (04): : 427 - 427
  • [25] It is too early to routinely use free PSA for prostate cancer screening
    Villers, A
    Chautard, D
    PROGRES EN UROLOGIE, 2000, 10 (04): : 618 - 621
  • [26] Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancer
    Loeb, Stacy
    Carter, H. Ballentine
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2009, 27 (06) : 583 - 584
  • [27] PSA, prostate cancer screening, clinical practice guidelines and the "wise judge"
    Gion, Massimo
    BIOCHIMICA CLINICA, 2018, 42 (04) : 321 - 326
  • [28] Prostate cancer screening: clinical impact of WHO calibration of Beckman Coulter Access® prostate-specific antigen assays
    Fillee, Catherine
    Tombal, Bertrand
    Philippe, Marianne
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2010, 48 (02) : 285 - 288
  • [29] Variation in PSA results from different assay platforms: Clinical impact on 2,304 patients undergoing prostate cancer screening.
    Link, RE
    Shariat, S
    Nguyen, CV
    Farr, A
    Weinberg, AD
    Morton, RA
    Bernard, DW
    Slawin, KM
    JOURNAL OF UROLOGY, 2002, 167 (04): : 101 - 102
  • [30] Re: Reconsidering Prostate Cancer Mortality - The Future of PSA Screening The future of PSA screening by reconsidering prostate cancer mortality
    Borghesi, Marco
    Suardi, Nazareno
    Terrone, Carlo
    EUROPEAN UROLOGY, 2020, 78 (06) : 929 - 929
12345